All News

The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.

"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms," offers an in-depth look at the disorder and promising therapies.

Caissa Troutman, MD, stresses the importance of building trust with patients through active listening and consistent, non-judgmental communication.

Your daily dose of the clinical news you may have missed.

Marketed as Omvoh, the therapy is already approved as a first-in-class treatment for moderately to severely active ulcerative colitis.

Shagun Bindlish, MD, board member of the American Diabetes Association, details available options for treating venous disease in patients with obesity.

Guidance from the Advisory Committee on Immunization Practices on best practices for COVID-19 vaccination continues to evolve, Hopkins explained.

Early proof-of-concept phase 1a data from the trial is anticipated in the third quarter of 2025.

Agitation in Alzheimer disease is not limited to the later stages, geriatric psychiatrist George Grossberg, MD, explains; look for it across the spectrum.

More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.

FDA action date set for July 26, 2025.

Your daily dose of the clinical news you may have missed.

Peter McAllister, MD,

Annual incidence of dementia will double in White adults and triple among Black adults. The updated estimates place the lifetime risk of developing dementia after age 55 at 42%.

Obesity medicine expert Caissa Troutman, MD, suggests using annual physicals as a "gateway" to identify patients with obesity with elevated blood pressure.

A new analysis of patient reported outcomes from the PATHFINDER study indicate the potential clinical benefit of early cancer detection.

The geriatric psychiatrist refers in this interview to agitation in Alzheimer disease, a significant neuropsychiatric symptom that should not be dismissed.

Neurologist and clinical investigator Peter McAllister, MD, is eager to make progress in research on diagnosis and treatment and to hear more patient voices.